Business and Trade Committee
House of Commons, London SW1A 0AA
020 7219 8586 - Commonsbtc@parliament.uk - www.parliament.uk/CommonsBTC - @CommonsBTC

Chris Stokes
President and General Manager,
UK, Ireland and Northern Europe
Eli Lilly
[By email]

18 August 2025

Dear Chris Stokes,

**Increase in price of Mounjaro**

Following the announcement on Thursday 14 August that the price of Eli Lilly medication, Mounjaro, would increase for UK patients using private prescriptions on 1 September, I am writing to inquire about the motivation for the change in price and the likely impact on UK consumers.

It has been reported that the price of a month's supply of the highest doses of Mounjaro "will increase from £122 to £330, a 170 per cent rise, while prices for lower doses will climb by between 45 per cent and 138 per cent".[1]

In light of this news I would be grateful for answers to the following questions:

1. Whether the price rises reported are accurate and when they will be introduced?
2. What impact the price rises will have on UK consumers and sales in the UK? In particular, how will the sudden price rise – and resultant necessity to stop the medication for some patients – impact their health?
3. What the justification for the sudden price rises are? Whether the possibility of US trade action stimulated the price rise?
4. Whether price rises in the UK will impact prices in other countries? In particular, in the US?
5. What Eli Lilly policy is on ensuring competitive pricing of its medication in the UK?
6. Whether there will be any price rises for Mounjaro for the NHS?

I would appreciate a response to this letter by Monday 1 September 2025.

Yours sincerely,

Liam Byrne

**Chair of the Business and Trade Committee**

[1] Financial Times, 15 August 2025 "UK patients rush to buy obesity jab ahead of 170% price rise"